Home Cart Sign in  
Chemical Structure| 755038-65-4 Chemical Structure| 755038-65-4

Structure of Volasertib
CAS No.: 755038-65-4

Chemical Structure| 755038-65-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Volasertib (BI 6727) is an orally active, highly potent, and ATP-competitive inhibitor of Polo-like kinase 1 (PLK1) with an IC50 of 0.87 nM. It inhibits PLK2 and PLK3 with IC50 values of 5 nM and 56 nM, respectively, inducing mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, exhibits significant antitumor activity in various cancer models.

Synonyms: BI 6727

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Volasertib

CAS No. :755038-65-4
Formula : C34H50N8O3
M.W : 618.81
SMILES Code : O=C(C1=CC=C(C(OC)=C1)NC2=NC3=C(C=N2)N(C([C@H](N3C(C)C)CC)=O)C)N[C@H]4CC[C@@H](CC4)N5CCN(CC5)CC6CC6
Synonyms :
BI 6727
MDL No. :MFCD20926414
InChI Key :SXNJFOWDRLKDSF-XKHVUIRMSA-N
Pubchem ID :10461508

Safety of Volasertib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • PLK1

    PLK1, IC50:0.87 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
HMC-1.1 and HMC-1.2 cells 500 nM 24 h To evaluate the effects of Volasertib on the clonogenic potential and apoptosis of HMC-1 cells, results showed that Volasertib significantly reduced clonogenic growth and induced apoptosis in HMC-1 cells. PMC9999558
HGSOC cells 0.001–10 µM 72 h To evaluate the cytotoxicity of Volasertib on HGSOC spheroids and organoids PMC11764263
HNSCC cell lines 0.018 to 9.613 μM 72 h To evaluate the sensitivity of HNSCC cell lines to Volasertib, results showed diverse sensitivity among the cell lines PMC5404895
HNSCC cell lines 50 nM To assess the effect of Volasertib on cell cycle and apoptosis in HNSCC cell lines, results showed drug-induced G2/M cell cycle arrest and apoptosis PMC5404895
H1975 50 nM 72 h Induction of a mesenchymal phenotype significantly increased PARP cleavage and DNA damage after Volasertib treatment, indicating enhanced apoptosis. PMC6505578
HCC4006 50 nM 72 h Induction of a mesenchymal phenotype significantly increased PARP cleavage and DNA damage after Volasertib treatment, indicating enhanced apoptosis. PMC6505578
HCC366 50 nM 72 h Induction of a mesenchymal phenotype significantly increased PARP cleavage and DNA damage after Volasertib treatment, indicating enhanced apoptosis. PMC6505578
MIA PaCa-2-R 20 nM 24 h To evaluate the sensitivity of Volasertib in KRASG12Ci-resistant cells, results showed that Volasertib significantly reduced c-Myc levels and induced apoptosis. PMC10724920
NCI-H358-R 20 nM 24 h To evaluate the sensitivity of Volasertib in KRASG12Ci-resistant cells, results showed that Volasertib significantly reduced c-Myc levels and induced apoptosis. PMC10724920
SW1573 20 nM 24 h To evaluate the sensitivity of Volasertib in KRASG12Ci-resistant cells, results showed that Volasertib significantly reduced c-Myc levels and induced apoptosis. PMC10724920
K562-S cells 1 μM 24 h To evaluate the effect of Volasertib on the expression and activation of AURKA, PLK1, and FOXM1 in K562-S cells. The results showed that Volasertib significantly reduced the expression and activation of AURKA, PLK1, and FOXM1. PMC6533706
K562-R cells 1 μM 24 h To evaluate the effect of Volasertib on the expression and activation of AURKA, PLK1, and FOXM1 in K562-R cells. The results showed that Volasertib significantly reduced the expression and activation of AURKA, PLK1, and FOXM1. PMC6533706

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice AA TNBC xenograft model Intraperitoneal injection 15 mg/kg Twice weekly for 28 days To evaluate the effect of Volasertib on the growth of AA TNBC xenograft tumors, the results showed that Volasertib significantly inhibited the growth of AA TNBC tumors. PMC9832024
mice oral squamous tongue tumor model intravenous injection 30 mg/kg weekly for 21 days To evaluate the antitumor effect of Volasertib in an AJUBA-mutant HNSCC mouse model, results showed significant reduction in tumor volume PMC5404895
Mice NSCLC cell line and patient-derived xenograft (PDX) models Intravenous 30 mg/kg Weekly for 5 weeks Volasertib alone significantly reduced tumor growth in mesenchymal models but was less effective in epithelial models. The combination of Volasertib and cMet inhibitors led to significant tumor regression. PMC6505578
Nude mice KRASG12C-mutant tumor models Oral 20 mg/kg Once per week for 3–4 weeks To evaluate the inhibitory effect of Volasertib combined with KRASG12Ci on KRASG12C-mutant tumors, results showed that the combination therapy significantly inhibited tumor growth and overcame drug resistance. PMC10724920
Mice NSG mice Intraperitoneal injection 5 mg/kg Every other day, up to 20 injections To evaluate the therapeutic effect of Volasertib in combination with Venetoclax on T-ALL mouse models, the results showed that the combination treatment significantly reduced tumor burden and improved the survival rate of the mice. PMC10484999

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01023958 Neoplasms Phase 2 Completed - United States, California ... More >> 1230.2.5 Boehringer Ingelheim Investigational Site Beverly Hills, California, United States 1230.2.10 Boehringer Ingelheim Investigational Site Los Angeles, California, United States United States, Florida 1230.2.34 Boehringer Ingelheim Investigational Site Miami, Florida, United States 1230.2.29 Boehringer Ingelheim Investigational Site Orlando, Florida, United States United States, Illinois 1230.2.6 Boehringer Ingelheim Investigational Site Chicago, Illinois, United States 1230.2.17 Boehringer Ingelheim Investigational Site Joliet, Illinois, United States United States, Louisiana 1230.2.24 Boehringer Ingelheim Investigational Site Metairie, Louisiana, United States United States, Maryland 1230.2.1 Boehringer Ingelheim Investigational Site Baltimore, Maryland, United States United States, Nevada 1230.2.25 Boehringer Ingelheim Investigational Site Las Vegas, Nevada, United States 1230.2.36 Boehringer Ingelheim Investigational Site Las Vegas, Nevada, United States United States, New Hampshire 1230.2.19 Boehringer Ingelheim Investigational Site Lebanon, New Hampshire, United States United States, New York 1230.2.20 Boehringer Ingelheim Investigational Site New York, New York, United States 1230.2.23 Boehringer Ingelheim Investigational Site New York, New York, United States United States, North Carolina 1230.2.12 Boehringer Ingelheim Investigational Site Charlotte, North Carolina, United States United States, Pennsylvania 1230.2.4 Boehringer Ingelheim Investigational Site Philadelphia, Pennsylvania, United States United States, Texas 1230.2.38 Boehringer Ingelheim Investigational Site Beaumont, Texas, United States 1230.2.41 Boehringer Ingelheim Investigational Site Tyler, Texas, United States 1230.2.43 Boehringer Ingelheim Investigational Site Webster, Texas, United States United States, Virginia 1230.2.44 Boehringer Ingelheim Investigational Site Fairfax, Virginia, United States Taiwan 1230.2.51 Boehringer Ingelheim Investigational Site Tainan, Taiwan 1230.2.50 Boehringer Ingelheim Investigational Site Taipei, Taiwan Less <<
NCT00969553 Neoplasms PHASE1 COMPLETED 2025-09-11 1230.16.886002 Boehringer Inge... More >>lheim Investigational Site, Tainan, Taiwan|1230.16.886001 Boehringer Ingelheim Investigational Site, Taipei, Taiwan Less <<
NCT01023958 - Completed - -
NCT01121406 Ovarian Neoplasms Phase 2 Completed - Belgium ... More >> 1230.18.32003 Boehringer Ingelheim Investigational Site Brussel, Belgium 1230.18.32004 Boehringer Ingelheim Investigational Site Edegem, Belgium 1230.18.32002 Boehringer Ingelheim Investigational Site Gent, Belgium 1230.18.32001 Boehringer Ingelheim Investigational Site Leuven, Belgium France 1230.18.3321A Boehringer Ingelheim Investigational Site Angers Cedex 9, France 1230.18.3307A Boehringer Ingelheim Investigational Site Bordeaux cedex, France 1230.18.3301A Boehringer Ingelheim Investigational Site Caen, France 1230.18.3322A Boehringer Ingelheim Investigational Site Lille Cedex, France 1230.18.3313A Boehringer Ingelheim Investigational Site Lyon, France 1230.18.3312A Boehringer Ingelheim Investigational Site Nantes cedex 02, France 1230.18.3308A Boehringer Ingelheim Investigational Site Nice cedex, France 1230.18.3314A Boehringer Ingelheim Investigational Site Paris Cedex 20, France 1230.18.3302A Boehringer Ingelheim Investigational Site Paris, France 1230.18.3309A Boehringer Ingelheim Investigational Site Pierre-Bénite cedex, France 1230.18.3305A Boehringer Ingelheim Investigational Site Reims cedex, France 1230.18.3320A Boehringer Ingelheim Investigational Site Saint-Brieuc cedex, France 1230.18.3311A Boehringer Ingelheim Investigational Site Strasbourg, France 1230.18.3310A Boehringer Ingelheim Investigational Site Toulouse Cedex 9, France 1230.18.3315A Boehringer Ingelheim Investigational Site Vandoeuvre les Nancy cedex, France Slovakia 1230.18.42101 Boehringer Ingelheim Investigational Site Bratislava, Slovakia 1230.18.42103 Boehringer Ingelheim Investigational Site Poprad, Slovakia Spain 1230.18.34006 Boehringer Ingelheim Investigational Site Badalona, Spain 1230.18.34001 Boehringer Ingelheim Investigational Site Barcelona, Spain 1230.18.34005 Boehringer Ingelheim Investigational Site Barcelona, Spain 1230.18.34007 Boehringer Ingelheim Investigational Site Girona, Spain 1230.18.34004 Boehringer Ingelheim Investigational Site L'Hospitalet de Llobregat, Spain 1230.18.34002 Boehringer Ingelheim Investigational Site Madrid, Spain 1230.18.34003 Boehringer Ingelheim Investigational Site Madrid, Spain Sweden 1230.18.46005 Boehringer Ingelheim Investigational Site Linköping, Sweden 1230.18.46001 Boehringer Ingelheim Investigational Site Stockholm, Sweden 1230.18.46003 Boehringer Ingelheim Investigational Site Uppsala, Sweden Less <<
NCT01121406 - Completed - -
NCT00804856 Leukemia, Myeloid, Acute Phase 2 Active, not recruiting August 2, 2019 Austria ... More >> LKH-Univ. Hospital Graz Graz, Austria, 8036 Belgium AZ Sint-Jan Brugge Brugge, Belgium, 8000 Brussels - UNIV Saint-Luc Bruxelles, Belgium, 1200 UZ Leuven Leuven, Belgium, 3000 Canada, Migration Data CHUS Fleurimont Sherbrooke, Migration Data, Canada, J1H 5N4 Canada, Ontario Princess Margaret Cancer Centre Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Montreal General Hospital - McGill University Health Centre Montreal, Quebec, Canada, H3G 1A4 France HOP Clémenceau, Hémato, Caen Caen, France, 14033 HOP, Centre Hospitalier René Dubos, Hémato, Paris Cergy Pontoise Cedex, France, 95303 HOP Dupuytren Limoges, France, 87042 HOP Herriot Lyon Cedex 03, France, 69437 CTR, fondation Paschetta, Hémato, Nice Nice Cedex 2, France, 06189 HOP Saint-Louis Paris cedex 10, France, 75475 CTR Henri Becquerel Rouen Cedex, France, 76088 Germany Campus Virchow-Klinikum, Berlin Berlin, Germany, 13353 Universitätsklinikum Frankfurt Frankfurt/Main, Germany, 60590 Universitätsklinikum Freiburg Freiburg, Germany, 79106 Universitätsklinikum Hamburg-Eppendorf Hamburg, Germany, 20246 Universitätsklinikum Heidelberg Heidelberg, Germany, 69120 Universitätsklinikum Schleswig-Holstein, Campus Kiel Kiel, Germany, 24116 Universitätsklinikum Münster Münster, Germany, 48149 Universitätsklinikum Ulm Ulm, Germany, 89081 Italy A.O. Spedali Civili di Brescia Brescia, Italy, 25123 ASST Grande Ospedale Metropolitano Niguarda Milano, Italy, 20162 Azienda Ospedaliera Policlinico di Modena Modena, Italy, 41100 Norway Haukeland Universitetssykehus Bergen, Norway, N-5021 Oslo Universitetssykehus HF, Ullevål sykehus Oslo, Norway, N-0450 Less <<
NCT00824408 Carcinoma, Non-Small-Cell Lung Phase 2 Completed - Bahamas ... More >> 1230.5.00118 Boehringer Ingelheim Investigational Site Nassau, Bahamas Canada, Alberta 1230.5.00104 Boehringer Ingelheim Investigational Site Edmonton, Alberta, Canada Canada, British Columbia 1230.5.00114 Boehringer Ingelheim Investigational Site Kelowna, British Columbia, Canada 1230.5.00109 Boehringer Ingelheim Investigational Site Surrey, British Columbia, Canada 1230.5.00107 Boehringer Ingelheim Investigational Site Vancouver, British Columbia, Canada Canada, Ontario 1230.5.00105 Boehringer Ingelheim Investigational Site Hamilton, Ontario, Canada 1230.5.00119 Boehringer Ingelheim Investigational Site Kitchener, Ontario, Canada 1230.5.00116 Boehringer Ingelheim Investigational Site Oshawa, Ontario, Canada 1230.5.00108 Boehringer Ingelheim Investigational Site Ottawa, Ontario, Canada 1230.5.00110 Boehringer Ingelheim Investigational Site Toronto, Ontario, Canada Canada, Quebec 1230.5.00102 Boehringer Ingelheim Investigational Site Montreal, Quebec, Canada 1230.5.00106 Boehringer Ingelheim Investigational Site Montreal, Quebec, Canada Less <<
NCT02273388 Neoplasms PHASE1 COMPLETED 2021-04-06 1230.1.32002 Boehringer Ingelh... More >>eim Investigational Site, Brussels, Belgium|1230.1.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium Less <<
NCT01721876 Leukemia, Myeloid, Acute Phase 3 Active, not recruiting December 31, 2019 -
NCT00824408 - Completed - -
NCT01957644 Myelodysplastic Syndromes ... More >> Leukemia, Myelomonocytic, Chronic Less << Phase 1 Terminated - France ... More >> Boehringer Ingelheim Investigational Site Marseille, France Boehringer Ingelheim Investigational Site Paris, France Germany Boehringer Ingelheim Investigational Site Berlin, Germany Boehringer Ingelheim Investigational Site Dresden, Germany Boehringer Ingelheim Investigational Site Düsseldorf, Germany Boehringer Ingelheim Investigational Site Frankfurt/Main, Germany Boehringer Ingelheim Investigational Site Freiburg, Germany Boehringer Ingelheim Investigational Site Hamburg, Germany Boehringer Ingelheim Investigational Site Hannover, Germany Boehringer Ingelheim Investigational Site Kassel, Germany Boehringer Ingelheim Investigational Site Leipzig, Germany Boehringer Ingelheim Investigational Site Mannheim, Germany Boehringer Ingelheim Investigational Site München, Germany Boehringer Ingelheim Investigational Site Ulm, Germany Less <<
NCT01206816 Neoplasms Phase 1 Completed - Belgium ... More >> 1230.20.32001 Boehringer Ingelheim Investigational Site Bruxelles, Belgium 1230.20.32003 Boehringer Ingelheim Investigational Site Edegem, Belgium 1230.20.32002 Boehringer Ingelheim Investigational Site Gent, Belgium Less <<
NCT00969761 Neoplasms Phase 1 Completed - Belgium ... More >> 1230.6.3201 Boehringer Ingelheim Investigational Site Bruxelles, Belgium 1230.6.3202 Boehringer Ingelheim Investigational Site Leuven, Belgium Less <<
NCT02198482 Acute Myeloid Leukemia (AML) ... More >> High-risk Myelodysplastic Syndrome (MDS) Less << Phase 2 Terminated(development program... More >> of study drug volasertib was stopped by Boehringer Ingelheim due to manufacturing problems) Less << - Germany ... More >> Hospital Aschaffenburg Aschaffenburg, Germany, 63739 Helios Hospital Bad Saarow Bad Saarow, Germany, 15526 Vivantes Hospital Am Urban Berlin, Germany, 10967 Vivantes Hospital Neukölln Berlin, Germany, 12351 Charite Berlin Campus Virchow Hospital Berlin, Germany, 13353 Knappschaftskrankenhaus Bochum-Langendeer Bochum, Germany, 44892 University Hospital Bonn Bonn, Germany, 53105 Community Hospital Braunschweig Braunschweig, Germany, 38114 Hospital Darmstadt Darmstadt, Germany, 64283 University Hospital Düsseldorf Düsseldorf, Germany, 40225 Hospital Essen, Protestant Hospital Essen-Werden Essen, Germany, 45239 Hospital Esslingen Esslingen, Germany, 73730 Malteser Hospital St. Franziskus Flensburg, Germany, 24939 Hospital Frankfurt-Höchst Frankfurt, Germany, 65929 Medical Care Unit Osthessen Fulda, Germany, 36043 University Hospital Gießen Gießen, Germany, 35392 Wilhelm-Anton-Hospital Goch Goch, Germany, 47574 University Hospital Göttingen Göttingen, Germany, 37075 University Hospital Hamburg-Eppendorf Hamburg, Germany, 20246 Asklepios Hospital Altona Hamburg, Germany, 22763 Hospital Hanau Hanau, Germany, 63450 KRH Hospital Siloah-Oststadt-Heidehaus Hannover, Germany, 30459 Hannover Medical School Hannover, Germany, 30625 SLK-Hospital Heilbronn Heilbronn, Germany, 74078 Marienhospital Herne Herne, Germany, 44625 University Hospital des Saarlandes Homburg/Saar, Germany, 66421 Community Hospital Karlsruhe Karlsruhe, Germany, 76133 University Hospital Schleswig-Holstein Kiel, Germany, 24105 Caritas Hospital Lebach Lebach, Germany, 66822 Hospital Lippe-Lemgo Lemgo, Germany, 32657 University Hospital Magdeburg Magdeburg, Germany, 39120 University Hospital Johannes Gutenberg Mainz Mainz, Germany, 55131 Johannes Wesling Hospital Minden Minden, Germany, 32429 Stauferklinikum Schwäbisch-Gmünd Mutlangen, Germany, 73557 Hospital Schwabing München, Germany, 80804 Hospital rechts der Isar München München, Germany, 81675 Hospital Oldenburg Oldenburg, Germany, 26133 Hospital Passau Passau, Germany, 94032 Hospital Stuttgart Stuttgart, Germany, 70174 Diakonie Hospital Stuttgart Stuttgart, Germany, 70176 Hospital Traunstein Traunstein, Germany, 83278 Mutterhaus der Borromäerinnen Trier, Germany, 54290 Hospital Barmherzige Brüder Trier Trier, Germany, 54292 University Hospital Tübingen Tübingen, Germany, 72076 University Hospital Ulm Ulm, Germany, 89081 Less <<
NCT01022853 - Completed - -
NCT01145885 Neoplasms PHASE1 COMPLETED 2025-11-10 1230.23.36001 Boehringer Ingel... More >>heim Investigational Site, Budapest, Hungary Less <<
NCT01022853 Neoplasms Phase 1 Completed - Italy ... More >> 1230.7.39002 Boehringer Ingelheim Investigational Site Ancona, Italy 1230.7.39001 Boehringer Ingelheim Investigational Site Milano, Italy Less <<
NCT01971476 - Completed - -
NCT02875002 Relapsed and Refractory Aggres... More >>sive B- and T-cell Lymphomas Lymphoma Less << Phase 1 Withdrawn September 2018 United States, Connecticut ... More >> Yale Cancer Center New Haven, Connecticut, United States, 06511 United States, Maryland Sidney Kimmel Comprehensive Cancer Baltimore, Maryland, United States, 21287 United States, Virginia Massey Cancer Center Richmond, Virginia, United States, 23298 Less <<
NCT01971476 Leukemia Neop... More >>lasms Less << Phase 1 Completed - Belgium ... More >> UNIV UZ Gent Gent, Belgium, 9000 Czechia University Hospital Motol Prague, Czechia, 150 06 France INS Curie Paris, France, 75248 Germany Universitätsklinikum Köln (AöR) Köln, Germany, 50937 Italy Osp. Pediatrico Bambin Gesù Roma, Italy, 00165 Less <<
NCT01772563 Neoplasms Phase 1 Active, not recruiting April 15, 2019 Hungary ... More >> PRA Hungary Ltd., Phase I. Clinical Pharmacology Unit Budapest, Hungary, 1077 National Institute of Oncology Budapest, Hungary, 1122 Less <<
NCT02757248 PTCL CTCL Phase 1 Withdrawn(Boehringer Ingelheim... More >> is discontinuing their volasertib development program) Less << - -
NCT02003573 Leukemia, Myeloid, Acute Phase 1 Terminated - United States, Connecticut ... More >> Boehringer Ingelheim Investigational Site New Haven, Connecticut, United States United States, Missouri Boehringer Ingelheim Investigational Site St. Louis, Missouri, United States United States, New York Boehringer Ingelheim Investigational Site Lake Success, New York, United States United States, Texas Boehringer Ingelheim Investigational Site Houston, Texas, United States Less <<
NCT01348347 Neoplasms Phase 1 Completed - Japan ... More >> 1230.15.001 National Cancer Center Hospital, Chuo-ku, Tokyo, Japan Less <<
NCT02905994 AML Phase 1 Withdrawn(Funding Withdrawn) - United States, Massachusetts ... More >> Massachusetts general Hospital Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Less <<
NCT01348347 - Completed - -
NCT02527174 Leukemia, Myeloid, Acute ... More >> Leukemia, Monocytic, Acute Leukemia, Myelomonocytic, Acute Leukemia, Erythroblastic, Acute Leukemia, Megakaryoblastic, Acute Less << Phase 1 Withdrawn(Volasertib no longer... More >> available) Less << September 2018 Canada, Alberta ... More >> Tom Baker Cancer Centre Calgary, Alberta, Canada, T2N 4N2 University of Alberta Hospital Edmonton, Alberta, Canada, T6G 2G3 Less <<
NCT02721875 Myelodysplastic Syndromes Phase 1 Terminated - Japan ... More >> University of Fukui Hospital Fukui, Yoshida-gun, Japan, 910-1193 Less <<
NCT02861040 Recurrent Adult Acute Lymphobl... More >>astic Leukemia Refractory Adult Acute Lymphoblastic Leukemia Less << Phase 1 Withdrawn - United States, California ... More >> Stanford University Palo Alto, California, United States, 94304 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21231 Less <<
NCT02721875 - Terminated - -
NCT02201329 Myelodysplastic Syndromes ... More >> Leukemia, Myelomonocytic, Chronic Less << Phase 1 Completed - Japan ... More >> Boehringer Ingelheim Investigational Site Aichi, Nagoya, Japan Boehringer Ingelheim Investigational Site Gunma, Maebashi, Japan Boehringer Ingelheim Investigational Site Nagasaki, Nagasaki, Japan Boehringer Ingelheim Investigational Site Tokyo, Sinagawa-ku, Japan Less <<
NCT02201329 - Completed - -
NCT02722135 Leukemia, Myeloid, Acute PHASE1 WITHDRAWN 2025-09-18 Boehringer Ingelheim Investiga... More >>tional Site, Gent, Belgium Less <<
NCT01662505 Leukemia, Myeloid, Acute PHASE1 COMPLETED 2025-05-15 Boehringer Ingelheim Investiga... More >>tional Site, Chuo-ku, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Isehara, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Maebashi, Gunma,, Japan|Boehringer Ingelheim Investigational Site, Nagasaki, Nagasaki, Japan|Boehringer Ingelheim Investigational Site, Nagoya-shi, Aichi, Japan|Boehringer Ingelheim Investigational Site, Yoshida-gun, Fukui, Japan Less <<
NCT01662505 Leukemia, Myeloid, Acute PHASE1 COMPLETED 2025-05-15 Boehringer Ingelheim Investiga... More >>tional Site, Chuo-ku, Tokyo, Japan|Boehringer Ingelheim Investigational Site, Isehara, Kanagawa, Japan|Boehringer Ingelheim Investigational Site, Maebashi, Gunma,, Japan|Boehringer Ingelheim Investigational Site, Nagasaki, Nagasaki, Japan|Boehringer Ingelheim Investigational Site, Nagoya-shi, Aichi, Japan|Boehringer Ingelheim Investigational Site, Yoshida-gun, Fukui, Japan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.62mL

0.32mL

0.16mL

8.08mL

1.62mL

0.81mL

16.16mL

3.23mL

1.62mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories